EA201600347A3 - HYBRID PROTEIN, DNA, GENETIC CONSTRUCTION, PRODUCER, VACCINE BASED ON HYBRID PROTEIN FOR PREVENTION AND TREATMENT OF TUBERCULOSIS (OPTIONS) - Google Patents

HYBRID PROTEIN, DNA, GENETIC CONSTRUCTION, PRODUCER, VACCINE BASED ON HYBRID PROTEIN FOR PREVENTION AND TREATMENT OF TUBERCULOSIS (OPTIONS)

Info

Publication number
EA201600347A3
EA201600347A3 EA201600347A EA201600347A EA201600347A3 EA 201600347 A3 EA201600347 A3 EA 201600347A3 EA 201600347 A EA201600347 A EA 201600347A EA 201600347 A EA201600347 A EA 201600347A EA 201600347 A3 EA201600347 A3 EA 201600347A3
Authority
EA
Eurasian Patent Office
Prior art keywords
hybrid protein
tuberculosis
prevention
treatment
vaccine
Prior art date
Application number
EA201600347A
Other languages
Russian (ru)
Other versions
EA201600347A2 (en
EA037849B1 (en
Inventor
Илья Владимирович Духовлинов
Антон Иосифович Орлов
Екатерина Алексеевна Федорова
Екатерина Николаевна Черняева
Original Assignee
Илья Владимирович Духовлинов
Антон Иосифович Орлов
Екатерина Алексеевна Федорова
Екатерина Николаевна Черняева
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Илья Владимирович Духовлинов, Антон Иосифович Орлов, Екатерина Алексеевна Федорова, Екатерина Николаевна Черняева filed Critical Илья Владимирович Духовлинов
Publication of EA201600347A2 publication Critical patent/EA201600347A2/en
Publication of EA201600347A3 publication Critical patent/EA201600347A3/en
Publication of EA037849B1 publication Critical patent/EA037849B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/255—Salmonella (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Группа изобретений относится к молекулярной биологии, биотехнологии, медицине и может быть использована для осуществления профилактики и лечения туберкулеза. Предложены гибридные белки, включающие иммуногенные фрагменты белков Ag85B, Tb10.4 M.tuberculosis, FliC S.Typhimurium, соединенные гибкими мостиками, кодирующие полинуклеотиды, генетические конструкции для экспрессии полинуклеотидов, продуценты и варианты вакцины для профилактики и лечения туберкулеза на основе описанного гибридного белка, потребитель разработанной вакцины - человек, либо животное. Предложенная вакцина имеет эффективность, превышающую таковую БЦЖ. Изобретения, заявленные для получения данной вакцины, обеспечивают ее безопасность и простоту при производстве и применении.The group of inventions relates to molecular biology, biotechnology, medicine and can be used to implement the prevention and treatment of tuberculosis. Hybrid proteins, including immunogenic fragments of proteins Ag85B, Tb10.4 M. tuberculosis, FliC S. Typhimurium, connected by flexible bridges, encoding polynucleotides, genetic constructs for the expression of polynucleotides, producers and variants of the vaccine for the prevention and treatment of tuberculosis based on the described hybrid protein, are proposed. The consumer of a developed vaccine is a human or an animal. The proposed vaccine has an efficacy greater than that of BCG. Inventions claimed to obtain this vaccine ensure its safety and simplicity in production and use.

EA201600347A 2015-05-25 2016-05-24 Fusion protein, dna, genetic construct, producer, fusion protein-based vaccine for tuberculosis prevention and treatment (versions) EA037849B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2015119607A RU2615440C2 (en) 2015-05-25 2015-05-25 Fusion protein, dna, genetic construct, recombinant cell, fusion protein-based vaccine for tuberculosis prevention and treatment (versions)

Publications (3)

Publication Number Publication Date
EA201600347A2 EA201600347A2 (en) 2016-09-30
EA201600347A3 true EA201600347A3 (en) 2017-01-30
EA037849B1 EA037849B1 (en) 2021-05-27

Family

ID=54362746

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201600347A EA037849B1 (en) 2015-05-25 2016-05-24 Fusion protein, dna, genetic construct, producer, fusion protein-based vaccine for tuberculosis prevention and treatment (versions)

Country Status (2)

Country Link
EA (1) EA037849B1 (en)
RU (1) RU2615440C2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201791906A1 (en) * 2017-09-24 2019-03-29 Илья Владимирович ДУХОВЛИНОВ VACCINE ON THE BASIS OF A HYBRID PROTEIN AND DNA FOR PREVENTION AND TREATMENT OF TUBERCULOSIS (OPTIONS)
CN111424045A (en) * 2020-04-02 2020-07-17 湖南科诺康美生命科技有限公司 Optimized gene of salmonella typhimurium flagellin and preparation method thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005061534A2 (en) * 2003-12-23 2005-07-07 Statens Serum Institut Improved tuberculosis vaccines
DK2167124T3 (en) * 2007-06-29 2012-10-29 Statens Seruminstitut Use of monomycolylglycerol (MMG) as an adjuvant
US20110189208A1 (en) * 2008-09-24 2011-08-04 Andrew William Heath Tb vaccine
RU2524133C2 (en) * 2012-11-15 2014-07-27 Федеральное государственное унитарное предприятие "Государственный научно-исследовательский институт особо чистых биопрепаратов" Федерального медико-биологического агентства Escherichia coli BACTERIA STRAIN - PRODUCER OF RECOMBINANT FLAGELLIN

Also Published As

Publication number Publication date
RU2615440C2 (en) 2017-04-04
RU2015119607A (en) 2015-10-27
EA201600347A2 (en) 2016-09-30
EA037849B1 (en) 2021-05-27

Similar Documents

Publication Publication Date Title
PH12019500709A1 (en) Anti-lag-3 antibodies and methods of use thereof
PH12017501583A1 (en) Novel proteins specific for cd137
MX2022010376A (en) De-immunized shiga toxin a subunit effector polypeptides for applications in mammals.
AU2018240515A1 (en) Nucleic acids encoding CRISPR-associated proteins and uses thereof
MX2020001996A (en) Anti-cd137 molecules and use thereof.
MD3551660T2 (en) Anti-CTLA-4 antibodies and methods of use thereof
MX2017014908A (en) Trispecific binding proteins and methods of use.
PE20151180A1 (en) ANTI-CEACAM5 ANTIBODIES AND USES OF THEM
SA518390954B1 (en) Therapeutic HPV18 Vaccines
TR201908550T4 (en) Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications.
MX2017014716A (en) Anti-cancer fusion polypeptide.
BR112016022814A8 (en) pharmaceutical composition and its method of preparation, nucleic acid, and medical device or medical kit
MX2019012223A (en) Anti-cd137 antibodies and methods of use thereof.
BR112019005587A2 (en) recombinant binding proteins and their use
CY1120772T1 (en) Mutated OspA FRAGMENTS AND RELATED METHODS AND USES
BR112016024352A2 (en) "recombinant listeria strain, recombinant listeria, pharmaceutical composition, and methods of inducing an immune response against a tumor or cancer in a human and listeria individual"
MX2017014730A (en) Muteins of human lipocalin 2 with affinity for glypican-3 (gpc3).
BR112016027024A2 (en) specific binding polypeptides and their uses
UA117045C2 (en) Fusion protein inhibiting angiogenesis or growth and use thereof
MX2018000447A (en) Novel proteins specific for lag-3.
CY1124667T1 (en) MODIFIED RNA ENCODING VEGF-A POLYPEPTIDES, PHARMACEUTICAL FORM, AND USES RELATED THEREOF
EA201491513A1 (en) RECOMBINANT STRAINS ESCHERICHIA COLI
TR201910117T4 (en) Mutant fragments of OspA and related methods and uses.
MX2022002635A (en) Angiopoietin-like 4 antibodies and methods of use.
EA201600347A3 (en) HYBRID PROTEIN, DNA, GENETIC CONSTRUCTION, PRODUCER, VACCINE BASED ON HYBRID PROTEIN FOR PREVENTION AND TREATMENT OF TUBERCULOSIS (OPTIONS)